Related Experiment Videos
Postmenopausal hormone therapy. Is it useful for coronary prevention?
1Department of Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Cardiology Clinics
|March 21, 1998
Summary
Postmenopausal hormone therapy may reduce coronary disease risk, especially for high-risk women. However, potential risks like breast cancer and venous thromboembolism must be considered alongside benefits such as osteoporosis prevention.
Area of Science:
- Cardiovascular Medicine
- Endocrinology
- Women's Health
Background:
- Coronary heart disease (CHD) is a leading cause of death for postmenopausal women.
- Estrogen deficiency significantly impacts women's cardiovascular risk.
- Women experience poorer outcomes from cardiovascular events compared to men.
Purpose of the Study:
- To evaluate the role of postmenopausal hormone therapy (HT) in preventing coronary disease in women.
- To assess the balance between cardiovascular benefits and non-cardiovascular risks of HT.
Main Methods:
- Review of observational studies and epidemiologic data on hormone therapy use in postmenopausal women.
- Analysis of data stratified by coronary disease risk and severity.
- Consideration of both coronary and non-coronary outcomes associated with HT.
Main Results:
- Observational studies suggest HT may reduce mortality risk, particularly in women with existing or high risk of coronary disease.
- Greater benefits observed in women with severe, angiographically defined coronary disease.
- Non-coronary risks include endometrial hyperplasia, breast cancer, and venous thromboembolism.
- Non-coronary benefits include reduced osteoporosis, fractures, and vasomotor symptoms.
Conclusions:
- Postmenopausal hormone therapy may offer significant cardioprotection for women with established or high risk of coronary disease.
- The decision to use HT requires careful consideration of individual risk profiles, balancing potential cardiovascular benefits against non-coronary risks like breast cancer.